688089.SH
ST嘉必优
SSE · Healthcare · Biotechnology · CN
CNY 7.56
+0.67%Year over year
Reported trailing growth
- Revenue
- -29.7%
- EBITDA
- —
- EBIT
- -63.0%
- EPS
- -62.1%
- Free cash flow
- +381.9%
- Operating cash flow
- +38.1%
Forward estimates
Based on analyst estimates
- Revenue
- +15.6%
- EBITDA
- -42.5%
- EPS
- -41.0%
Three-year CAGR
- Revenue
- +9.1%
- EBITDA
- +39.8%
- EBIT
- +43.0%
- Net income
- +30.7%
- EPS
- +31.3%
- Free cash flow
- +425.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026